Dr. Fudala, Assistant Professor, University of North Texas Health Science Center (UNTHSC)
Dr. Fudala received a Master's in Biochemistry (1999; B-Cell Leukemia) from the University of Lodz, Poland, and a Ph.D. in Microbiology and Immunology at the same University (2004; Urinary Tract Infection). Dr. Fudala joined the laboratory at the UTHSC at Tyler, which specialized in studying host reactions in ALI/ARDS, for his first post-doctoral training (2004-2010). For his second post-doctoral training (2010-2012), Dr. Fudala joined the laboratory at UNTHSC, where he was engaged in developing new fluorescence, plasmonics, and nanotechnology techniques in biomedical applications. Over the last 10 years, Dr. Fudala worked in fluorescence and probe development. Recently, Dr. Fudala's interests have expanded to include fluorescence-based methods in molecular and cellular imaging and biochemical/biophysical applications of new nanophotonics processes in the biomedical and diagnostic fields, especially to develop rHDL delivery systems to cure cancers.
Dr. Fudala, Assistant Professor, University of North Texas Health Science Center (UNTHSC)
Dr. Fudala received a Master's in Biochemistry (1999; B-Cell Leukemia) from the University of Lodz, Poland, and a Ph.D. in Microbiology and Immunology at the same University (2004; Urinary Tract Infection). Dr. Fudala joined the laboratory at the UTHSC at Tyler, which specialized in studying host reactions in ALI/ARDS, for his first post-doctoral training (2004-2010). For his second post-doctoral training (2010-2012), Dr. Fudala joined the laboratory at UNTHSC, where he was engaged in developing new fluorescence, plasmonics, and nanotechnology techniques in biomedical applications. Over the last 10 years, Dr. Fudala worked in fluorescence and probe development. Recently, Dr. Fudala's interests have expanded to include fluorescence-based methods in molecular and cellular imaging and biochemical/biophysical applications of new nanophotonics processes in the biomedical and diagnostic fields, especially to develop rHDL delivery systems to cure cancers.